CROI 2017 Program and Information

Program and Agenda

298 CLONES OF HIV-INFECTED CELLS ARISE INVIVO IN THE FIRST FEWWEEKS FOLLOWING INFECTION David Wells 1 , Jennifer M. Zerbato 2 , Joann D. Kuruc 3 , Joseph J. Eron 3 , Mary F. Kearney 4 , John Coffin 5 , Frank Maldarelli 4 , Xiaolin Wu 1 , John W. Mellors 2 , Stephen H. Hughes 4 1 Liedos Biomed Rsr, Inc, Frederick, MD, USA, 2 Univ of Pittsburgh, Pittsburgh, PA, USA, 3 Univ of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 4 NCI, Frederick, MD, USA, 5 Tufts Univ, Boston, MA, USA 299LB RESURGENCE OF HIV-1 FOUNDER VIRUSES FOLLOWING ANTIRETROVIRAL TREATMENT INTERRUPTION Morgane Rolland 1 , Eric Sanders-Buell 1 , Meera Bose 1 , Nittaya Phanuphak 2 , Mark de Souza 3 , Nelson L. Michael 1 , Merlin L. Robb 1 , Jintanat Ananworanich 1 , Sodsai Tovanabutra 1 , for the RV254/SEARCH 010 Study Groups Poster P-E8 MODIFYING THE RESERVOIR: CLINICAL STUDIES Poster Hall - 4 EF 2:30 PM - 4:00 PM 323 HIV-1 DNA BLOOD RESERVOIRS ARE NOT ALTERED BY HIGH- DOSE CHEMOTHERAPY FOR LYMPHOMA Heloise M. Delagreverie 1 , Antoine Chaillon 2 , Laurence Gerard 1 , Marie-Laure Néré 1 , Romain Palich 3 , Sylvain Chawki 1 , Lionel Galicier 1 , Eric Oksenhendler 1 , Marie-Laure Chaix Baudier 1 , Constance Delaugerre 1 1 Saint Louis Hosp, Paris, France, 2 Univ of California San Diego, San Diego, CA, USA, 3 Pitié-Salpêtrière Hosp, Paris, France 324 THE IMPACT OF IMMUNOGLOBULIN IN PRIMARY HIV INFECTION ON THE HIV RESERVOIR Juan Tiraboschi 1 , Prabhjeet Phalora 2 , Nicola Robinson 2 , Emily Hopkins 2 , Steve Kaye 3 , Jeremy Sanderson 1 , Sarah Fidler 3 , Paul Klenerman 2 , John Frater 2 , Julie Fox 4 1 Guy’s and St Thomas’ NHS Fndn Trust, London, UK, 2 Univ of Oxford, Oxford, UK, 3 Imperial Coll London, London, UK, 4 King’s Coll London, London, UK 325 RATES OF VIRAL DECAY INHIV-1 CONTROLLERS INITIATING ANTIRETROVIRAL THERAPY Jonathan Li 1 , Heloise M. Delagreverie 2 , Rachel Getz 1 , Christina Lalama 3 , Ronald Bosch 3 , Daniel R. Kuritzkes 1 , Alan Landay 4 , Florencia Pereyra 1 , Paul E. Sax 1 , for the AIDS Clinical Trials Group A5308 Study Team 1 Brigham and Women’s Hosp, Harvard Med Sch, Boston, MA, USA, 2 Saint Louis Hosp, Paris, France, 3 Harvard Univ, Boston, MA, USA, 4 Rush Univ Med Cntr, Chicago, IL, USA 326 PEGYLATED IFN-ALPHA-2B DECREASES LATENT HIVMEASURES IN ART-SUPPRESSED SUBJECTS Livio Azzoni 1 , Emmanouil Papasavvas 1 , Nicolas Chomont 2 , Qingsheng Li 3 , Bonnie J. Howell 4 , Douglas D. Richman 5 , Pablo Tebas 6 , KaramMounzer 7 , Jay Kostman 8 , Luis Montaner 1 1 Wistar Inst, Philadelphia, PA, USA, 2 Univ de Montréal, Montreal, QC, Canada, 3 Univ of Nebraska, Lincoln, NE, USA, 4 Merck & Co, Inc, West Point, PA, USA, 5 Univ of California San Diego, La Jolla, CA, USA, 6 Univ of Pennsylvania, Philadelphia, PA, USA, 7 Philadelphia FIGHT, Philadelphia, PA, USA, 8 Philadelphia FIGHT Community Hlth Cntrs, Philadelphia, PA, USA 1 US Military HIV Rsr Prog, Silver Spring, MD, USA, 2 Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand, 3 SEARCH, Thai Red Cross AIDS Rsr Cntr, Bangkok, Thailand

Poster Sessions • Thursday

CROI 2017 174